Many of the claims made for the benefits of health tests marketed to UK consumers are unsubstantiated, with little information provided on their potential harms and limitations, finds an assessment of the websites of 50 commercial test vendors, published in the open access journal BMJ Open.
The sector is predicted to increase globally from US$1.6 billion in 2023 to US$3.2 billion by 2029, so there's an urgent need for stronger regulatory protection for consumers, insist the researchers.
Commercial tests can include blood tests, medical imaging, physical examination and physiological testing, sold individually or in 'packages', explain the researchers.
But there is scant evidence of their effectiveness in healthy people, and concerns have been raised about their accuracy and the risk of false positive/negative results, overdiagnosis, overtreatment, and 'mental and/or physical harm', they add.
The researchers therefore wanted to gauge the current availability of commercially available screening tests marketed to UK consumers and to find out whether current practice protects them and the NHS from the consequences of inappropriate testing.
They identified a sample of 50 UK individuals, companies, and clinics—including major providers—promoting health tests to healthy people in the UK online.
The tests included blood tests (eg full blood counts, liver function, genetic testing); and urine, stool, and saliva tests (eg urinary protein, gut microbiome, cortisol); physiological tests (eg pulmonary function tests, grip strength, and ECGs); medical imaging (eg chest x-rays, MRI, and ultrasound scans); physical examination (eg pelvic and breast examinations).
Clinics offered a wide range of tests for healthy people, which aren't recommended by the NHS. Prices ranged from £6.99 (Kidney Albumin Rapid Test' for urine, taken at home) to £14,000 ('Platinum Assessment', multiple tests carried out in a clinic).
Many 'health checks' were sold in 'packages'. The 'well woman premium assessment' or 'executive MOT' could contain multiple tests and types of tests, for example. Other sales included packages with additional 'add-ons'.
While many vendors described in detail the tests on offer, others simply stated, for example, 'vital blood checks' without specifying which ones were being tested. Some clinics stated that doctors 'may recommend' other tests after discussion on the day.
Contrary to NHS advice and guidelines, 12 vendors offered mammograms to normal-risk, symptomless women under the age of 50; 45 offered to test lipids and Hb1ac (for fasting blood glucose) to well adults under 40; 31 offered follicle-stimulating hormone tests to all women over 45; and 28 offered qFIT (to test hidden blood in the stool) to adults under 50.
Thirteen organisations offered breast exams and 9 offered pelvic exams to people without any worrying symptoms; 14 offered testicular exams. The NHS doesn't recommend these for people who don't have symptoms, note the researchers.
Thirty six of the 50 vendors made claims for earlier diagnosis and better outcomes; 48 made claims for better knowledge of health; 16 made claims for living longer, despite no evidence for this; and 25 made a claim for reassurance.
Most (70%) of the vendors didn't explain the limitations of testing or its potential harms, including that of intimate physical examinations. In all, 15 made mention, either in full or partially, of the downsides of testing; 9 on overdiagnosis or false positives; 8 on underdiagnosis or false negatives; and 9 on inaccuracy.
Despite some vendors including a report with a doctor, many still asked purchasers to involve their own (NHS) doctor.
The Care Quality Commission regulated 36 vendors, and doctors either owned or worked with 41. Nurses worked in 11 organisations, pharmacists in 3, and a healthcare assistant in 1. But there was little information on any of this on many of the websites, note the researchers.
The researchers also canvassed the views of a group of citizens brought together for the purposes of this study. Their reasons for considering commercial tests included ease of access and hoping purchase would assist NHS interactions. But they also expressed the need for help with understanding test results: several clinics offered this only on payment of an additional fee.
The dynamic nature of the internet searches may have missed some tests available to the public and the search was limited to the UK, acknowledge the researchers. Not all information about tests given to customers may have been available online either, they add.
"While it is possible that appropriate, high-quality health testing bought directly by consumers could fill gaps in NHS service delivery, it is also possible that poor-quality screening tests will negatively impact citizens through false positives (false alarms), false negatives (false reassurance) and loss of personal resources with little or no value gained by individuals," they point out.
"NHS primary care is already experiencing the impacts of follow-up of test results initiated by consumers rather than the NHS," they highlight.
And they conclude: "Compared with the sale of pharmaceutical products, there are far more safeguards around sales, advertising, promotion and regulation of providers. The regulation around sales of health tests to the public is far less developed, despite their capability of harm.
"We suggest that gaps in regulation, particularly proactive approaches to health claims, should be urgently addressed."